β-Адреноблокатор с уникальными характеристиками – небиволол

1. Диагностика и лечение артериальной гипертензии. Проект Российских рекомендаций. Кардиоваск. тер. и проф. 2008; 4 (Прил.).
2. Gillman M, Kannel W, Belanger A, D'Agostino R. Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am Heart J 1993; 125: 1148–54.
3. Singh BN. Morbidity and mortality in cardiovascular disorders: impact of reduced heart rate. J Cardiovascular Pharmacol Therapeutics 2001; 6 (4): 313–33.
4. Kaplan NM. Multiple risk factors for coronary heart disease in patients with hypertension. J Hypertension 1995; 13 (2): 1–58.
5. McInnes GT. Hypertension and coronary artery disease: cause and effect. J Hypertens 1995; 13 (2): 49–56.
6. Julius S. Effect of sympathetic overactivity on cardiovascular prognosis in hypertension. Eur Heart J 1998; 19 (F): 14–8.
7. ESH-ESC Guidelines Committee. 2007 guidelines for the management of arterial hypertension. J Hypertension 2007; 25: 1105–87.
8. Zanchetti A. Clinical pharmacodynamics of nebivolol: new evidence of nitric oxide-mediated vasodilating activity and peculiar haemodynamic properties in hypertensive patients. Blood Press Suppl 2004; 1: 17–32.
9. Ignarro LJ. Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation betablocker. Blood Press Suppl 2004; 1: 2–16.
10. Agabiti Rosei E, Rizzoni D. Metabolic Profile of Nebivolol, a b-Adrenoceptor Antagonist with Unique Characteristics. Drugs 2007; 67 (8): 1097–107.
11. Van Nueten L, De Cree J. Nebivolol: Comparison of the effects of dl-nebivolol, d-nebivolol, l-nebivolol, atenolol, and placebo on exercise-induced increases in heart rate and systolic blood pressure. Cardiovasc Drugs Therapy 1998; 12: 339–44.
12. Mason RP, Kalinowski L et al. Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation 2005; 12: 3795–801.
13. McNeely W, Goa KL. Nebivolol in the management of essential hypertension: a review Drugs 1999; 57: 644–51.
14. Simon G, Johnson ML. Comparison of antihypertensive and B1-adrenoreceptor antagonist effect of nebivolol and atenolol in essential hypertension. Clin Exper Hypertens 1993; 15: 501–9.
15. Cheymol G, Woestenborghs R, Snoeck E et al. Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. Eur J Clin Pharmacol 1997; 51: 493–8.
16. Gu Z-M, Robinson RA, Cai L et al. Metabolism Study Of 14C-Nebivolol In Humans With Different CYP2D6 Genotypes. AAPS PharmSci 2003; 5 (4): 3362.
17. Weber MA. The role of new b-blockers in treating cardiovascular disease. Am J Hypertens 2005; 18: 169–75.
18. Ambrosioni E, Borghi C. Tolerability of nebivolol in clinical trials comparing it with other selective beta-blockers is the treatment of hypertension. A meta-analysis. High Blood Press Cardiovasc Prevent 2005; 12 (1): 27–35.
19. Kamp O, Sieswerda GT, Visser CA. Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension. Am J Cardiol 2003; 92: 344–8.
20. Celik T, Iyisoy A et al. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients. J Hypertens 2006; 24 (3): 591–6.
21. Rosei EA, Rizzoni D, Comini S et al. the Nebivolol-Lisinopril Study Group. Evaluation of the efficacy and tolerability of nebivolol versus lisinopril in the treatment of essential arterial hypertension: A randomized, multicenter, double blind study. Blood Press 2003; 12 (suppl. 1): 30–5.
22. Van Bortel LM, Bulpitt C, Fici F. Quality of life and antihypertensive effect with nebivolol and losartan. Am J Hypertens 2005; 18: 1060–6.
23. Mazza A, Gil-Extremera B et al. Nebivolol vs amlodipine as first-line treatment of essential arterial hypertension in the elderly. Blood Press 2002; 11: 182–8.
24. LacourciПre Y, Poirer L et al. Comparative effects of a new cardioselective beta-blocker nebivolol and nifedipine sustained-release on 24-hour ambulatory blood pressure and plasma lipoproteins. J Clin Pharmacol 1992; 32: 660–6.
25. Ames RP. The effects of antihypertensive drugs on serum lipids and lipoproteins. II. Non-diuretic drugs. Drugs 1986; 32: 335–57.
26. LacourciПre Y, Poirier I, Boucher S, Spendar J. Comparative effects of diltiazem sustained-release formulation and metoprolol on ambulatory blood pressure and plasma lipoproteins. Clin Pharmacol Ther 1990; 48: 318–24.
27. Weiss RJ, Weber MA, Carr AA et al. Nebivolol in the treatment of patients with stage 1 and stage 2 hypertension: Results of a randomized, double-blind, placebo-controlled study. Am J Hypertension 2005; 18: A96.
28. Ko DT, Hebert PR, Coggey CS et al. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002; 288: 351–7.
29. Van Nueten L, Taylor FR, Robertson JI. Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomized trial. J Human Hypertens 1998; 12: 135–40.
30. Doumas M, Tsakiris A et al. Beneficial effects of switching from b-blockers to nebivolol on the erectile function of hypertensive patients. Asian J Androl 2006; 8: 177–82.
31. Predel HG, Mainka W et al. Integrated effects of the vasodilating beta-blocker nebivolol on exercise performance, energy metabolism, cardiovascular and neurohormonal parameters in physically active patients with arterial hypertension. J Hum Hypertens 2001; 15 (10): 715–21.
32. Flather MD, Shibata MC et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26 (3): 215–25.
33. Schmidt AC, Graf C, Brixius K, Scholze J. Blood pressure-lowering effect of nebivolol in hypertensive patients with type 2 diabetes mellitus. The YESTONO Study. Clin Drug Investigat 2007; 27 (12): 841–9.

Л.Г.Ратова, И.Е.Чазова

РК НПК Росмедтехнологий, Москва